Hello from Madrid, and welcome back to Endpoints Weekly! I’m at #ESMO26 with my colleagues Ayisha Sharma and Reynald ...
Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results